Nuclear receptor agonist-driven modification of inflammation and amyloid pathology enhances and sustains cognitive improvements in a mouse model of Alzheimer's disease by Casali, Brad T. et al.
RESEARCH Open Access
Nuclear receptor agonist-driven
modification of inflammation and amyloid
pathology enhances and sustains cognitive
improvements in a mouse model of
Alzheimer’s disease
Brad T. Casali1,2, Erin G. Reed-Geaghan1 and Gary E. Landreth1,2*
Abstract
Background: Alzheimer’s disease (AD) is a highly prevalent neurodegenerative disorder characterized by pathological
hallmarks of beta-amyloid plaque deposits, tau pathology, inflammation, and cognitive decline. Treatment remains a
clinical obstacle due to lack of effective therapeutics. Agonists targeting nuclear receptors, such as bexarotene, reversed
cognitive deficits regardless of treatment duration and age in murine models of AD. While bexarotene demonstrated
marked efficacy in decreasing plaque levels following short-term treatment, prolonged treatment did not modulate
plaque burden. This suggested that plaques might reform in mice treated chronically with bexarotene and that
cessation of bexarotene treatment before plaques reform might alter amyloid pathology, inflammation, and
cognition in AD mice.
Methods: We utilized one-year-old APP/PS1 mice that were divided into two groups. We treated one group of
mice for 2 weeks with bexarotene. The other group of mice was treated for 2 weeks with bexarotene followed by
withdrawal of drug treatment for an additional 2 weeks. Cognition was evaluated using the novel-object recognition
test either at the end of bexarotene treatment or the end of the withdrawal period. We then analyzed amyloid
pathology and microgliosis at the conclusion of the study in both groups.
Results: Bexarotene treatment enhanced cognition in APP/PS1 mice similar to previous findings. Strikingly, we observed
sustained cognitive improvements in mice in which bexarotene treatment was discontinued for 2 weeks. We observed a
sustained reduction in microgliosis and plaque burden following drug withdrawal exclusively in the hippocampus.
Conclusions: Our findings demonstrate that bexarotene selectively modifies aspects of neuroinflammation in a
region-specific manner to reverse hippocampal-dependent cognitive deficits in AD mice and may provide insight
to inform future studies with nuclear receptor agonists.
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Background
Alzheimer’s disease (AD) is a prominent neurodegenerative
disorder that occurs in later life. Its pathological hallmarks
include neurofibrillary tangles composed of intracellular
hyperphosphorylated tau and extracellular deposits of
β-amyloid (Aβ) species which comprise plaques in the
brain parenchyma. Specifically, age-related deficits in Aβ
clearance are associated with the accumulation of neuro-
toxic Aβ species and plaques that are linked to cognitive
deficits [1, 2]. Additional pathological consequences that
accompany Aβ accumulation include the dysregulated
production of pro-inflammatory cytokines from resident
microglia and astrocytes [3, 4]. Thus, strategies which en-
hance the clearance of Aβ, resolution of inflammation,
and improve cognition may be of therapeutic utility.
Nuclear receptors are ligand-activated transcription
factors that act to coordinate and control the expression
of many genes involved in clearance of Aβ and inflam-
mation [5, 6]. ApoE is the major apolipoprotein of the
brain and functions to transport cholesterol and phos-
pholipids throughout the brain as high-density lipoproteins
(ApoE-HDLs) and plays a prominent role in Aβmetabolism
and deposition [7–9]. Formation of ApoE-containing high-
density lipoproteins (HDL) is facilitated by lipid transporter
ABCA1 which transfers cholesterol and phospholipids to
ApoE apolipoproteins. Importantly, the production of ApoE
and ABCA1 is transcriptionally controlled by activation of
nuclear receptors. The nuclear receptors liver X (LXR) or
peroxisome proliferator-activated (PPAR) receptors form
obligate heterodimers with retinoid X Receptor (RXR), and
upon ligand binding, promote target gene transcription.
Clearance of soluble Aβ species is dependent on ApoE and
its lipidation state [7]. Importantly, activation of nuclear
receptors also promotes transrepression of genes associated
with inflammation [10]. Nuclear receptor agonists amelior-
ate amyloid pathology by decreasing soluble Aβ levels,
promoting the phagocytosis of plaques, suppressing the
expression of inflammatory genes, and enhancing cog-
nition in various mouse models of AD [11–13].
RXR agonists represent attractive therapeutic agents
since RXR acts as the common heterodimer of nuclear
receptors LXR and PPAR, and the ligation of RXR
promotes transcription of genes associated with Aβ
clearance and abrogation of inflammation in AD mouse
models [8, 14–16]. Acute treatment with the RXR agonist
bexarotene promotes plaque clearance, but chronic bexaro-
tene treatment paradoxically does not affect plaque burden
[8]. We thus hypothesized that plaques may reform after
their initial clearance by bexarotene. Furthermore, bexaro-
tene may modulate Aβ dynamics since a single dose dimin-
ishes soluble Aβ levels by approximately 25% for up to
72 h [8]. The effects of amyloid reformation on pathology
and cognition after removal of a nuclear receptor agonist
have not been explored in an AD mouse model.
We report here that acute treatment with bexarotene
augments production of highly-lipidated ApoE-HDL parti-
cles, curtails microglial reactivity, reduces plaque burden,
and improves cognition in APP/PS1 mice. Surprisingly, des-
pite cessation of bexarotene treatment, APP/PS1-treated
mice continued to demonstrate sustained improvements in
cognition and abrogation of amyloid pathology for as long
as 2 weeks. Our findings imply nuclear receptor agonist
treatment and withdrawal profoundly alter the dynamics of
amyloid pathology and cognition in the brain. These
findings suggest that intermittent dosing strategies may




Antibodies were purchased from the following sources
and used at the indicated dilutions for Western blots
and immunostaining: Iba1 (Wako, #019-19741); 6E10
(Biolegend, #803001); ABCA1 (Novus NB400-105, 1:2500);
ApoE (sc-6384; 1:2000), β-actin (sc-1615; 1:10,000), and
GAPDH (sc-32233; 1:10,000, all purchased from Santa
Cruz Biotechnology); and β-tubulin (Licor #926-42211;
1:10,000). For Aβ ELISAs, Aβ 1-40 HRP-conjugated and
Aβ 1-42 HRP-conjugated antibodies were both purchased
from BioLegend (# 805407 and #805507, respectively) and
both used at 1:5000 dilutions. The anti-Aβ antibody (6E10)
was also purchased from BioLegend (#803017) and used to
capture Aβ at 1:1000 dilution for ELISAs. The clinical
formulation of bexarotene (Targretin™) is a micronized
form of the drug which exhibits sustained plasma levels
following oral administration and was obtained from
(Valeant Pharmaceuticals, 75 mg capsules). Thioflavin S
was purchased from Sigma (#T1892).
Study approval
All animal experiments utilized protocols which were
approved by the Case Western Reserve University School of
Medicine’s Institutional Animal Care and Use Committee
(IACUC).
In vivo animal treatment study design
Transgenic APPswe/PS1Δe9 (APP/PS1) mice, which
carry APPswe K595N/M596L mutation and a deletion of
exon 9 of human presenilin 1 [17], were purchased from
Jackson Laboratories (MMRRC stock #34832) and bred
in-house to generate experimental animal cohorts.
Animals were housed in a facility under 12-h light and
dark cycle and had access to food and water ad libitum.
Male and female transgenic (Tg) or wildtype (WT) mice
and littermate controls aged 12 months were used in all
studies. For bexarotene treatment and its discontinuation
(see Fig. 1), mice were divided into two groups: 14 days
bexarotene treatment alone (14 days on) or 14 days on
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bexarotene treatment and 14 days off bexarotene (14 days
on + + 14 days off). Targretin capsules were dispersed in
water and administered at 100 mg/kg by oral gavage daily
for 14 days for both groups, and water alone served as
vehicle control. After 14 days of either vehicle or bexaro-
tene treatment, the 14 days on + 14 days off group was
discontinued from vehicle or bexarotene treatment
without any handling for an additional 14 days. Novel
object recognition (NOR) was performed on either day
13 of the treatment for both groups or on day 27 for
the 14 days on + 14 days off group only. Mice in both
groups were euthanized on either day 14 or day 29 for
according to IACUC guidelines. For behavioral testing,
we used mixed sex groups for each time point. For
“14 days on” time point, the number and sexes of mice
used were WTvehicle (n = 10, six males and four females),
Tg vehicle (n = 4, all males), and Tg bexarotene (n = 6,
four males and two females). For “14 days on + 14 days
off,” the number and sexes of mice used were WT vehicle
(n = 14, seven males and seven females), Tg vehicle (n = 9,
eight males and one female), and Tg bexarotene (n = 10,
six males and four females). For molecular analyses, seven
or more animals were sampled for each treatment group.
For 6E10 and Iba1, the following sample sizes and sexes
were analyzed: 14 days on (vehicle, n = 5 M/2F; bexaro-
tene, n = 5 M/4F) and 14 days on + 14 days off (vehicle,
n = 6 M/1F; bexarotene, n = 4 M/3F).
Novel object recognition behavioral test
NOR was assessed and scored as previously described
[15]. Briefly, on either the 13th day of bexarotene treat-
ment or on the 27th day of bexarotene discontinuation,
mice were placed in a chamber with two identical objects
placed opposite to each other in the boxes’ corners. Mice
were allowed to explore the chamber freely for 10 min,
and the time spent investigating objects (T) was recorded.
Three hours later, one object was replaced with a different
object, but of similar size and shape, and mice were
returned to the chamber and allowed to explore the
objects for 5 min, and the duration of T spent investigat-
ing was recorded. Between tests, each chamber and object
was cleaned to eliminate residual odor. Following treat-
ment discontinuation, mice were subsequently retested
with different objects than those used previously. Animals
not performing the test (i.e., not interacting with any
objects) were excluded from the analysis (n = 1). Novel
object preference is displayed as the relative discrimination
index via the formula: [(Tnovel −Tfamiliar)/(Ttotal)].
Collection of tissue
Approximately 3 to 6 h following final bexarotene
administration or on the final day of the discontinuation
phase, animals were euthanized. The brains were removed
and divided into two hemispheres, and one hemisphere
was used for immunostaining, and the other hemisphere
was used for molecular analysis of protein, RNA, or Aβ
levels. For molecular analysis, the midbrain and cerebellum
were discarded and the remaining tissue (cortex and
hippocampus) was snap-frozen on dry ice and stored at
− 80 °C until analysis.
Immunostaining
One hemisphere of the brain was drop fixed in 4%
paraformaldehyde overnight at 4 °C. The brain was
then cryoprotected in increasing PBS/sucrose gradients,
embedded, and stored at − 80 °C until sectioning. The
brains were then sectioned on a cryostat (Leica) at
40 μm as freely floating sections in cryoprotection buffer
(30% glycerol [v/v] and 30% ethylene glycol [v/v] in PBS)
and stored at − 20 °C until staining. Thioflavin-S staining
was performed as previously described [8]. For 6E10 and
Iba1 staining, citric acid (Sigma, 251275) was used for
Fig. 1 Bexarotene treatment and discontinuation paradigm. Twelve-month-old APP/PS1 or wildtype (WT) littermate mice were divided into two
groups: “14 days on” or “14 days on + 14 days off.” Both groups were treated daily for 14 days with bexarotene or vehicle (water), and novel
object recognition (NOR) was performed on the 13th day, but the 14 days on the group was sacrificed on the 14th treatment day. The 14 days
on + 14 days off group was then subject to a discontinuation phase from bexarotene treatment for days 15 to 29, with NOR performed on
day 28 and sacrifice on day 29. Stars indicate molecular endpoints for each group consisting of protein, ELISA, and IHC analyses. Each treatment phase
was performed separately, and groups were combined for behavioral and molecular analyses
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antigen unmasking with modifications for free-floating
sections but essentially performed as previously described
[8]. For quantification of all immunostaining, two matched
medial and lateral sections from each animal were used,
images were captured on an inverted microscope with
similar exposure and gain settings for all samples, and
images were quantified with ImageJ (NIH) in a blinded
manner. Thioflavin-S hippocampal plaque counts were
normalized to total imaged hippocampal area deter-
mined using Adobe Photoshop.
Extraction of Aβ and Aβ ELISA
Aβ species from the brain homogenates were isolated as
previously described [18]. In brief, 0.4% diethylamine
(DEA) was added to homogenized tissue, and soluble
proteins were collected from the supernatant following
ultra-speed centrifugation. The remaining pellet was
sonicated in cold formic acid (FA), and FA-solubilized
proteins were collected from the supernatant following
another round of ultra-speed centrifugation. Soluble
(DEA) or insoluble (FA) extracts were then subjected
to Aβ ELISAs with 6E10 as capture antibody (see the
“Reagents” section, above). Detection of either Aβ 1-40
or Aβ 1-42 was used with specific detection antibodies
conjugated to HRP. ELISA levels were normalized to
total protein in each extract (either soluble or insoluble),
and results represented as fold change relative to vehicle-
treated animals.
Western blotting and native gel electrophoresis
For cell protein analysis, cultured cells were frozen at
− 80 °C until analysis, whereupon whole cell lysis was
performed with ice-cold RIPA buffer (50 mM Tris-HCl
pH 7.6, 150 mM NaCl, 1% Triton X-100 [v/v], 1%
sodium deoxycholate [v/v], 0.1% SDS [v/v], and 2 mM
EDTA) supplemented with protease inhibitor cocktail
(Sigma, #P8340). The brain tissue was homogenized with
a handheld homogenizer in cold tissue homogenization
buffer (2 mM Tris pH 7.4, 250 mM sucrose, 0.5 mM
EDTA, and 0.2 mM EGTA) with fresh protease inhibitors
added at the time of homogenization. Protein levels were
evaluated by resolving brain homogenates or astrocyte
lysates on 4–12% Bis-Tris gels (Life Technologies), with
samples reduced. To analyze lipidated ApoE-HDL
particles, the brain homogenates were resolved on 4–12%
Tris-Glycine gels (Life Technologies) under non-denaturing
conditions. All gels were transferred to PVDF membranes
and blocked, and primary antibodies were incubated
overnight at 4 °C (see the “Reagents” section above for
dilutions). Proteins were visualized using secondary
HRP-conjugated antibodies, and immunoblots were
analyzed using ImageJ (NIH).
RNA isolation and quantitative, real-time RT-PCR
To extract total RNA, an aliquot of brain homogenate
was mixed with RNABee (Amsbio) reagent, and the
solution was incubated on ice with chloroform. The
resultant aqueous layer was removed, and RNA was
isolated using PureLink RNA Mini Columns (Life
Technologies) according to manufacturer’s protocol.
Contaminating genomic DNA was removed, and com-
plementary DNA (cDNA) was reverse-transcribed with
High Capacity RNA to cDNA conversion kit (Life
Technologies) from equal concentrations of RNA across
samples. Pre-amplification (14 cycles) was subsequently
performed using TaqMan PreAmp Master Mix (Applied
Biosystems) with desired targets. Pre-amplified, diluted
cDNA was then used to run quantitative, real-time
RT-PCR on a StepOne Plus Real-Time PCR System with
desired TaqMan probes (all from Applied Biosystems;
probe numbers are available upon request). Expression
levels of mRNA were determined relative to housekeeping
genes GAPDH and 18S RNA, and data were normalized
to a wildtype calibrator sample. Statistics were performed
at the relative (delta Ct) level [19].
Primary astrocyte isolation and in vitro treatment
Mixed glial cultures were obtained from neonatal mouse
pups aged P0 to P3 from both sexes as previously
described [11]. In brief, the brains were removed (with
meninges intact) and minced, then the tissue was incubated
in trypsin/EDTA to dissociate cells. Cells were resuspended
in DMEM/F12 media supplemented with 10% heat-
inactivated fetal bovine serum (FBS) and incubated at
37 °C under 5% CO2 for 2 to 3 weeks. Following incu-
bation, astrocyte monolayers were enzymatically detached
with trypsin. Astrocytes were seeded into 6-well plates in
10% DMEM/F12 media, allowed to adhere for approxi-
mately 15 min, and media was aspirated, and new serum-
containing media was replaced to eliminate residual
microglia. For all cell treatments, astrocytes were serum
starved for at least 24 h in DMEM/F12 media. To model
bexarotene discontinuation in vitro, astrocytes were
treated with 10 nM bexarotene or DMSO. Following 24-h
treatment, one set of DMSO and bexarotene-treated
astrocytes were frozen at − 80 °C (bexarotene treatment).
The media from a parallel set of DMSO and bexarotene-
treated astrocytes were removed, the cells were washed
twice with PBS, and serum-free DMEM/F12 was replaced,
and cells returned to the incubator. Following 24 h, media
was removed, and the final set of DMSO and bexarotene-
treated astrocytes were frozen at − 80 °C (post-bexarotene
treatment). Cells were then lysed, and protein expression
was analyzed via Western blot detailed above. For quanti-
fication, Abca1 and ApoE protein levels were quantified
via ImageJ relative to loading control. Values for each
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group were then normalized to vehicle-treated samples
and represented as fold change.
Statistics
All error bars represent the standard error of the mean
(SEM), unless otherwise stated. Where appropriate, a
one- or two-way Student’s t test was used and noted in
the figure legends. Statistics were determined using
GraphPad Prism 5. P-values were considered statistically
significant when they were less than 0.05.
Results
Study treatment design
To ascertain the longevity of the effects of RXR agonist
bexarotene on amyloid pathology and cognition in APP/
PS1 transgenic mice, we designed a treatment paradigm
consisting of two treatment groups (Fig. 1). Twelve-
month-old transgenic APP/PS1 mice and their wildtype
(WT) littermates were divided into two groups: “14 days
on” or “14 days on + 14 days off.” Both groups were
treated daily with bexarotene (or vehicle control, water)
for 14 days; however, the “14 days on” group was sacrificed
on the 14th day of bexarotene treatment while the “14 days
on + 14 days off” group entered a discontinuation phase
where mice received no bexarotene or vehicle treatment
for 14 additional days. This second group was sacrificed on
day 29. Both groups were assessed by novel object recogni-
tion (NOR) tests on days 13 and 28.
Bexarotene significantly enhances and maintains short-term
memory improvements in vivo
We wished to test whether bexarotene treatment and its
discontinuation influenced short-term memory in a mouse
model of AD. We utilized the novel object recognition
(NOR) assay, testing the mice days 13 and 28 of the treat-
ment paradigm (Fig. 1). At both time points, we observed
significant short-term memory deficits in recognition of
the novel object in transgenic vehicle-treated APP/PS1
(Tg) mice compared to their WT vehicle-treated litter-
mates (Fig. 2). No significant differences were observed in
WT vehicle-treated mice at either time point. Bexarotene
treatment for 14 days resulted in a significant improve-
ment in recognition of the novel object compared to
vehicle-treated transgenic animals (Fig. 2, 14 days on,
Tg-vehicle vs Tg-bexarotene), consistent with previous
findings [20]. Remarkably, APP/PS1 mice discontinued
from bexarotene for 2 weeks still exhibited enhanced
novel object recognition. These data demonstrate that
bexarotene promotes long-lasting improvements in short-
term memory deficits in APP/PS1 mice, demonstrable
2 weeks after cessation of bexarotene treatment.
Bexarotene suppresses microglial reactivity and
selectively reduces plaque burden in the hippocampus
We have demonstrated that bexarotene can influence
AD pathology by suppressing the expression of genes
associated with inflammation in brain-resident microglia
in AD mice [16, 21]. To determine if improved cognition
was a result of reduced microglial activation, we
performed immunostaining for microglial marker Iba1.
Indeed, we observed significant reductions in Iba1
immunoreactivity in bexarotene-treated mice in both
“14 days on” and “14 days on + 14 days off” groups;
however, these observations were regional-specific and
restricted to the hippocampus (Fig. 3a, b, upper graphs).
Additionally, co-staining with 6E10, which labels both
dense and diffuse plaques, revealed significant reductions
in plaque burden in the hippocampus in bexarotene-
treated animals in both groups (Fig. 3a, b, lower graphs).
While bexarotene significantly reduced 6E10 plaque
burden in the cortex in the “14 days on” group, this
diminution was temporary as 6E10 plaque burden
rebounded to vehicle-treated levels in the “14 days on +
14 days off” group (Fig. 3b, lower graph).
Fig. 2 Bexarotene treatment corrects short-term memory deficits,
and cognitive improvements are maintained after removal in vivo.
Novel object recognition behavioral assay is displayed as the relative
discrimination index for wildtype (WT)-vehicle and APP/PS1 (Tg)-vehicle
or bexarotene-treated mice for each treatment group. The relative
discrimination index (see the “Methods” section) was determined as
the ratio between the difference in time spent investigating novel and
familiar objects to the total time investigating both objects. Relative
discrimination indexes of 0 represent lack of discrimination between
novel and familiar object while values greater than 0 represent
recognition of the novel object. **p < 0.01 and ***p < 0.001 with
respect to WT vehicle and #p < 0.05 and ##p < 0.01 with respect to
Tg vehicle, one-way ANOVA with Tukey post hoc test for multiple
corrections. Fourteen days on (n = 10, 4, 6) and 14 days on + 14 days
off (n = 14, 9, 10) for WT vehicle, Tg vehicle, Tg bexarotene, respectively.
The 14 days on group contains mice that were subsequently tested in
the 14 days on + 14 days off group
Casali et al. Journal of Neuroinflammation  (2018) 15:43 Page 5 of 11
Bexarotene treatment alone, or after its discontinuation,
did not significantly modify other metrics of amyloid
pathology. Dense-core plaque numbers, represented by
Thioflavin-S (ThioS+) staining, were unchanged in both
groups following bexarotene treatment in either the
brain region (Fig. 3c). We nonetheless observed a significant
decrease in cortical ThioS+ plaques between the “14 days
on” and the “14 days on + 14 days off” bexarotene-treated
groups (Fig. 3c). In a similar fashion, Aβ forms associated
with either the insoluble (FA) or soluble (DEA) extracts
were unchanged with bexarotene (Fig. 3d). However, this
finding could be a consequence of combined cortical and
hippocampal tissue homogenization—which may preclude
our ability to detect regional-specific effects of bexarotene
treatment on specific Aβ levels. Despite modest impacts on
amyloid pathology, bexarotene did indeed engage the LXR
target gene Abca1, resulting in elevated mRNA and protein
levels in the brain (Fig. 4a, top and bottom). Protein levels
of Abca1 remained significantly upregulated even after bex-
arotene removal (Fig. 4a, bottom) along with concomitant
elevations in lipidated ApoE-HDL levels at both time points
(Fig. 4c). Overall ApoE protein levels, however, remained
unchanged (Fig. 4b).
Thus, bexarotene acts to suppress microglial reactivity
and reduce 6E10 plaque burden in the hippocampus in
both treatment groups, an effect which may underlie
Fig. 3 Bexarotene selectively reduces microgliosis and decreases plaque burden in the hippocampus. a Representative hippocampal images
stained with Iba1 (green) and 6E10 (red) antibodies from vehicle- or bexarotene-treated animals from each treatment group. b Quantification of
the hippocampal (left) and cortical (right) Iba1 or 6E10 immunoreactivity. c Quantification of either the cortical (top) or hippocampal (bottom)
Thioflavin-S-positive (ThioS+) dense-core plaques. d ELISA results of Aβ isoforms (1-40 or 1-42) from insoluble (FA, left) or soluble (DEA, right)
extracts from the hippocampal and cortical homogenates. *p < 0.05, **p < 0.01, and ***p < 0.001, Student’s t test between groups indicated by
brackets. ns = not significant. N = 7 or more animals/group. Image magnification, × 20
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bexarotene’s salutary impact on cognition that we
observed in the NOR test (Fig. 2).
Protein levels of Abca1 remain significantly elevated
following removal of bexarotene in vitro
Two weeks after bexarotene treatment, we observed
significant elevations in the brain Abca1 protein expression
in APP/PS1 mice, suggesting that enhanced expression of
LXR target genes can be sustained despite the removal of
LXR agonist (Fig. 4). To ascertain whether effect could be
recapitulated in vitro, we treated primary astrocytes using
a paradigm which modeled bexarotene removal and moni-
tored the expression of LXR target genes, ApoE and Abca1.
As shown in Fig. 5a, following isolation of primary astro-
cytes, we treated two sets of astrocytes with vehicle
(DMSO) or bexarotene (10 nM). We performed protein
analysis of Abca1 and ApoE 24 h later in one set of astro-
cytes (this set of experiments is referred to as vehicle and
bexarotene analysis) while we washed and replaced the
medium in the second set of astrocytes (“vehicle-washout”
and “bexarotene-washout” analysis) for an additional 24 h.
Protein expression of Abca1 and ApoE was then evaluated
in the post-vehicle and post-bexarotene set of astrocytes.
While bexarotene did not induce a significant increase
in ApoE protein expression, we did find a significant
induction of ABCA1 protein in bexarotene-treated astro-
cytes after 24 h (Fig. 5b). Following an additional 24 h after
vehicle- or bexarotene-washout, Abca1 protein expression
in “vehicle-washout” remained unchanged relative to
vehicle levels. However, “bexarotene-washout” Abca1
protein expression continued to remain significantly
elevated compared to “vehicle-washout” Abca1 levels
(Fig. 5b). Interestingly, protein expression of “vehicle-
washout” ApoE significantly decreased relative to vehicle
levels. “Bexarotene-washout” protein levels of ApoE
remained comparable to bexarotene-treated astrocytes,
but “vehicle-washout” ApoE levels did not significantly
increase compared to “bexarotene-washout” levels (Fig. 5b).
Thus, utilizing an in vitro paradigm with primary astro-
cytes, we demonstrate that Abca1 protein remains
significantly elevated while ApoE levels remain unchanged
after bexarotene removal—data which support our in vivo
results (Fig. 4).
Fig. 4 Bexarotene treatment augments Abca1 expression and ApoE-HDL
levels in vivo. a Relative mRNA expression (top) or protein expression
(bottom) of Abca1 in each treatment group from the cortical and
hippocampal homogenates. b, c Quantification of ApoE protein
levels (b) or lipidated ApoE-HDL particles (c) from indicated groups.
Results are displayed as fold change vehicle-treated animals from
each treatment group. *p < 0.05, **p < 0.01, and ***p < 0.001, Student’s
t test between groups indicated by brackets. ns = not significant. Error
bars for mRNA expression in a represent 95% confidence intervals.
N = 7 or more animals/group
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Discussion
We investigated the dynamics of amyloid pathology and
cognition after RXR agonist discontinuation in a mouse
model of AD. Specifically, we demonstrate that acute
(14-day) bexarotene treatment restores short-term mem-
ory deficits of aged APP/PS1 mice and that this 14-day
treatment is sufficient to sustain short-term memory im-
provement even after cessation of drug administration
for as long as 2 weeks.
Ample evidence demonstrates the salutary cognitive
effects of nuclear receptor agonists in AD mouse models
which have been linked to their transcriptional control
of genes involved in the clearance of Aβ [7, 22–24] and
reviewed in Skerrett et al.[6]. Indeed, deletion of the LXR
target gene, Abca1, resulted in an enhanced β-amyloid
deposition in AD mouse models and worsened cognition.
Conversely, drugs that enhance Abca1 levels promote
clearance of Aβ through elevations in lipidated ApoE-
HDL particles and enhance cognition [25]. Abca1 acts to
transfer cholesterol and phospholipids to ApoE-based
HDL particles. Additionally, HDLs play pivotal roles in
cognition in the context of neurodegenerative disorders
[26]. Notably, we observed sustained protein expression of
the LXR target gene Abca1 and elevated lipidated ApoE-
HDL particles (Fig. 4) that mirrored hippocampal-specific
reductions in 6E10 plaque burden at both time points
(Fig. 3). While Abca1 protein remained elevated in ani-
mals discontinued from bexarotene treatment, Abca1
mRNA levels from these same animals diminished to
vehicle-treated levels. This finding could be due to
Fig. 5 Abca1 remains significantly elevated while ApoE expression does not change after bexarotene removal in vitro. a Diagram representing
the experimental procedure for analysis of bexarotene removal in primary astrocytes. Four groups of astrocytes were seeded: vehicle (white),
bexarotene (red), vehicle-washout (black), and bexarotene-washout (blue). Vehicle (DMSO) or 10 nM bexarotene was applied to astrocytes in
serum-free media (SFM) for 24 h after which vehicle and bexarotene samples were then used for protein analysis. Vehicle-washout and
bexarotene-washout plates were then washed with PBS, serum-free media replaced, and incubated for an additional 24 h. Following this time
point, vehicle-washout and bexarotene-washout samples were then used for protein analysis. b Quantification of each protein is represented as
fold change relative to vehicle-treated cells. *p < 0.05 and ***p < 0.001, one sample t test with respect to vehicle-treated cells. Brackets indicate
Student’s two-sample t test between indicated samples; #p < 0.05 and NS = not significant (exact p value = 0.111, Student’s t test with Welch’s
correction for unequal variances). Data are representative of four separate experiments
Casali et al. Journal of Neuroinflammation  (2018) 15:43 Page 8 of 11
bexarotene’s ability to promote transcription of other
LXR target genes that influence the stability of Abca1
at the protein level [27]. Our current data provide direct
support for previous observations that bexarotene requires
Abca1 expression to ameliorate behavioral impairments
and influence hippocampal Aβ levels, involving the gener-
ation of ApoE-HDLs in the brain [15], although other
mechanisms are also likely to be in play [21].
Nuclear receptor agonists counteract Aβ-induced
inflammation molecularly through transrepression of
pro-inflammatory gene transcription in microglia [28].
In the current study, we observed that bexarotene
blunted the hippocampal microglial activation at both time
points (Fig. 3), and this was correlated with improvements
in cognition (Fig. 2). Collectively, these data buttress past
work implicating salutary effects of nuclear receptor
agonists in murine models of AD. Indeed, we have shown
previously that bexarotene alone, or in combination with
other nuclear receptor agonists, can inhibit the expression
of pro-inflammatory genes and improve cognition in
various mouse models of AD [13–15, 21].
Secondary to their ability to block pro-inflammatory
gene production, nuclear receptor agonists may impact
inflammation through production of HDL particles
[26, 29]. The anti-inflammatory actions of ApoE-based
HDLs are well documented [26, 29, 30]. However, the
mechanisms that subserve the effects of ApoE-HDLs
on inflammation in the brain are unclear. Abca1 may
play an indirect role as APP/PS1 mice lacking Abca1
exhibit enhanced inflammatory genes and, notably,
augmented Iba1 reactivity in the hippocampus compared
to APP/PS1 mice [15].
With the current “14 days on” bexarotene treatment,
we did not observe the drastic reductions in amyloid
pathology described in our initial bexarotene study [8],
likely due to the analysis of older (1-year-old) mice. It is
noteworthy that older mice (approximately 11-month-old)
did not display as pronounced differences in amyloid
pathology as younger mice (6-month-old) treated with
bexarotene [8]. We observed that cortical plaque burden
quickly rebounded after bexarotene removal (Fig. 3) which
supports our initial findings that bexarotene’s ability to
clear plaque diminishes with chronic treatment [8].
Nevertheless, 14 days of bexarotene treatment enhanced
short-term memory in the novel object recognition assay
in APP/PS1 mice (Fig. 2). Fitz et al. reported that bexaro-
tene also reversed cognitive deficits in novel object
recognition in APP/PS1 mice. Though these authors
[20] used APP/PS1 mice that also expressed human
APOE3/4 isoforms, bexarotene treatment nevertheless
restored novel object recognition memory in both
groups of mice. Our findings compliment those of Fitz
and colleagues and support the targeting of nuclear
receptors as a therapeutic strategy [20].
Our initial study emphasized that cognitive improve-
ments may be uncoupled from plaque burden changes
and that microglia could play a critical role in bexaro-
tene’s ability to improve cognition in rodents [8, 31].
The current data bolster our initial claims and suggest
that microglia reactivity may subserve bexarotene’s
benefits in aged AD mice.
While other aspects of amyloid pathology were
unchanged with the current model and treatment
paradigm, bexarotene unexpectedly demonstrated a
marked selectivity in tempering microglial reactivity
and reducing plaque burden in the hippocampus.
These modifications in AD pathology support the
enhanced cognition in both bexarotene-treated and
discontinued animals since the hippocampus plays critical
roles in object recognition memory in mice [32]. We and
others [8, 20] have demonstrated that bexarotene decreases
interstitial fluid (ISF) levels of Aβ from the brain and that
enhanced clearance of ISF Aβ is facilitated by bexarotene.
It is possible that bexarotene alters clearance of ISF Aβ
levels to facilitate behavioral improvement over the
extended period but was not investigated in the current
study. Future studies should be aimed at discerning
whether bexarotene withdrawal can sustain cognitive
improvement in other hippocampal-dependent behavioral
tests.
We and others have previously reported brain region-
specific effects of nuclear receptor agonists on amyloid
pathology [9, 15, 22]. Although the basis of the region-
selective targeting of bexarotene, or other nuclear
receptor agonists actions, remains unexplained, other
factors may directly or indirectly contribute to these
findings. Bexarotene’s ability to reduce Aβ in the hippocam-
pus, but not the cortex, of AD mice was correlated with
each brain region’s relative Aβ burden [9]. Additionally,
others have reported similar hippocampal-directed effects
with LXR agonists in AD mouse models [22]. Moreover,
microglial immune-related gene expression varies in a
regional-specific manner which can shape the brain’s
response to aging-related neurodegeneration [33]. Thus,
bexarotene’s selective impact on AD pathology in the
hippocampus may be due to the susceptibility of certain
brain regions to accumulate Aβ deposits.
Conclusion
Our findings may inform the design of future studies
involving nuclear receptor agonists and also highlight
the therapeutic utility of RXR agonists. Recently, bexaro-
tene lowered the brain amyloid in non-ApoE4 carriers in
a small, proof-of-concept study in patients with AD, but
significant elevations in serum triglycerides were also
observed in bexarotene-treated patients [34]. Previously,
we demonstrated that elevations in triglycerides due to
bexarotene could be counteracted with omega-3 fatty
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acids in rodents [14]. However, the present data illus-
trate that bexarotene’s salutary effects on cognition last
for up to 2 weeks. This finding raises the possibility that
treatment schedules involving the withdrawal of RXR
agonists as an additional treatment strategy could be
beneficial in a translational environment. This will be
particularly critical where significant concerns of cardio-
vascular perturbations due to bexarotene may outweigh
clinical benefits in an elderly population.
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